Psychiatric manifestations of anti-NMDA receptor encephalitis in a man without tumor.

[1]  D. Keskin,et al.  A review of the current use of rituximab in autoimmune diseases. , 2009, International immunopharmacology.

[2]  A. Hida,et al.  RESPONSE OF ANTI-NMDA RECEPTOR ENCEPHALITIS WITHOUT TUMOR TO IMMUNOTHERAPY INCLUDING RITUXIMAB , 2008, Neurology.

[3]  Xiaoyu Peng,et al.  Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies , 2008, The Lancet Neurology.

[4]  P. Keck,et al.  Atypical Neuroleptic Malignant Syndrome: Diagnostic Controversies and Considerations , 2008, Pharmacotherapy.

[5]  J. Dalmau,et al.  Anti-NMDA receptor encephalitis in Japan , 2008, Neurology.

[6]  J. Dalmau,et al.  Limbic Encephalitis and Variants: Classification, Diagnosis and Treatment , 2007, The neurologist.

[7]  L. Sansing,et al.  A patient with encephalitis associated with NMDA receptor antibodies , 2007, Nature Clinical Practice Neurology.

[8]  Josep Dalmau,et al.  Paraneoplastic anti–N‐methyl‐D‐aspartate receptor encephalitis associated with ovarian teratoma , 2007, Annals of neurology.

[9]  L. Cavacini,et al.  Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. , 2006, The New England journal of medicine.

[10]  M. Bent,et al.  An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes , 2005, Journal of Neurology.

[11]  A. Thall,et al.  Intraventricular and Intravenous Treatment of a Patient with Refractory Primary CNS Lymphoma using Rituximab , 2002, Journal of Neuro-Oncology.

[12]  D. Farver.  Neuroleptic malignant syndrome induced by atypical antipsychotics , 2003, Expert opinion on drug safety.

[13]  J. Levenson.  Neuroleptic malignant syndrome. , 2007, The American journal of psychiatry.